NCT06266611

Cannabis for Palliative Care in Cancer

Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 185 (estimated)
• Sponsor: University of Colorado, Boulder · Academic / Other
• Sex: All
• Age: 25 Years
• Healthy volunteers: Not accepted

Summary

Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.

Conditions

• Sleep
• Anxiety
• Depression
• Pain

Interventions

Type	Name	Description
DRUG	fsCBD Cannabidiol	Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
DRUG	Placebo	Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
DRUG	bsCBD Cannabidiol	Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used

Timeline

• Start date: 2024-09-16
• Primary completion: 2028-05-30
• Completion: 2028-06-30
• First posted: 2024-02-20
• Last updated: 2025-08-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study